Chinese Hepatolgy ›› 2026, Vol. 31 ›› Issue (9): 1267-1272.

• Liver Failure • Previous Articles     Next Articles

Predictive value of peripheral blood CCL5 combined with CXCL14 for survival outcomes in patients with hepatitis B virus-related decompensated cirrhosis complicated by liver failure

Zhao Yanyan, Li Fuxiang, Liu Lulu   

  1. Department of Gastroenterology,Nanjing Pukou People's Hospital,Nanjing 221000,China
  • Received:2025-09-09 Online:2026-09-30 Published:2026-11-16
  • Contact: Liu Lulu,Email: 747058459@qq.com

Abstract: Objective This study aimed to investigate the predictive value of peripheral blood C-C motif chemokine ligand 5 (CCL5) combined with C-X-C motif chemokine ligand 14 (CXCL14) for survival outcomes in patients with hepatitis B virus-related decompensated cirrhosis (HBV-DC) complicated by liver failure (LF). Methods This prospective study included 106 patients with HBV-DC and LF (LF group) admitted to the Department of Gastroenterology of Nanjing Pukou People's Hospital between January 2022 and December 2024. According to cirrhosis staging, they were divided into the stage-3 group (n=37), the stage-4 group (n=41), and the stage-5 group (n=28). An additional 106 patients with HBV-DC without LF, 1:1-matched for admission time, were selected as the non-LF group. An enzyme-linked immunosorbent assay (ELISA) was used to measure peripheral blood levels of CCL5 and CXCL14. Levels of CCL5 and CXCL14 were compared across different cirrhosis stages in the LF group. Based on 90-day survival outcomes, patients were divided into the survival and the death groups. Multivariate logistic regression analysis was performed to identify factors influencing prognosis. Receiver operating characteristic (ROC) curve analysis was conducted to assess the predictive value of CCL5 and CXCL14, alone and in combination, for 90-day survival outcomes. Results Peripheral blood levels of CCL5 and CXCL14 in the LF group [9.39 (6.48, 13.47) ng/mL and 6.28 (3.99, 9.98) ng/mL] were significantly higher than those in the non-LF group [4.62 (3.66, 5.51) ng/mL and 3.23 (2.41, 3.98) ng/mL] (all P<0.001). CCL5 and CXCL14 levels increased progressively with cirrhosis severity across stages 3, 4 and 5 (all P<0.001). The 90-day mortality rate among HBV-DC patients with LF was 38.68% (41/106). Compared with the survival group, the death group had higher proportions of stage-5 cirrhosis (48.78% vs. 12.31%), hepatic encephalopathy (26.83% vs. 9.23%), sepsis (24.39% vs. 4.62%), gastrointestinal variceal bleeding (70.73% vs. 41.54%) and higher MELD scores (28.85 ± 6.89 vs. 21.95 ± 4.93), as well as elevated levels of CCL5 [13.63 (9.85, 15.50) ng/mL vs. 7.31 (4.38, 9.98) ng/mL] and CXCL14 [10.03 (6.80, 12.03) ng/mL vs. 4.91 (2.31, 7.41) ng/mL] (all P<0.05). Multivariate analysis identified sepsis [OR (95%CI): 5.985 (1.951~18.354), P=0.002], gastrointestinal variceal bleeding [OR (95%CI): 4.346 (1.283~14.720), P=0.018], MELD score [OR (95%CI): 1.357 (1.108~1.663), P=0.003], CCL5 [OR (95%CI): 1.934 (1.353~2.764), P<0.001] and CXCL14 [OR (95%CI): 1.962 (1.367~2.814), P<0.001] as independent risk factors for death. The area under the ROC curve (AUC) for CCL5, CXCL14, and their combination in predicting survival was 0.844, 0.833, and 0.936, respectively; the combined model outperformed either marker alone (Z=2.909 and 3.024, P=0.004 and 0.003, respectively). Conclusion Elevated peripheral blood levels of CCL5 and CXCL14 are closely associated with worsening cirrhosis and poor survival outcomes in patients with HBV-DC complicated by LF. The combination of CCL5 and CXCL14 enhances the predictive value for survival outcomes.

Key words: Hepatitis B virus-related decompensated cirrhosis, Liver failure, C-C motif chemokine ligand 5, C-X-C motif chemokine ligand 14, Survival outcomes, Predictive value